Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy
Joseph W. Rossano·Seema Mital·Cordula M. Wolf·Andrew L. Papez·Marta Gambra·Randall M. Bryant·Juan Alejos·Michael A. McCulloch·Georgia Sarquella‐Brugada·M.J. Bock·Aamir Jeewa·F. Bennett Pearce·Milind Y. Desai·Nicholas Favatella·Atefeh Javidialsaadi·Van Phung·Thomas A. Rano·Li Zhu·Joshua L. Dyme·Charles Canter
Among adolescent patients with obstructive hypertrophic cardiomyopathy, the reduction in left ventricular outflow tract obstruction was significantly greater with mavacamten than with placebo over a 28-week period. (Funded by Bristol Myers Squibb; SCOUT-HCM ClinicalTrials.gov number, NCT06253221.).